Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome (FORCE)
This study is currently recruiting participants.
Verified August 2017 by Grifols Biologicals Inc. ( Instituto Grifols, S.A. )
Instituto Grifols, S.A.
First Posted: June 27, 2014
Last Update Posted: August 3, 2017
Information provided by (Responsible Party):
Grifols Biologicals Inc. ( Instituto Grifols, S.A. )
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||September 2020|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|